Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|The Lancet Oncology|2025Cited by 13
Carfilzomib weekly 20/56 mg/m<sup>2</sup>, lenalidomide and dexamethasone for early relapsed refractory multiple myelomaValentine Richez, Xavier Leleu, Florent Plasse et al.|American Journal of Hematology|2018Cited by 7
Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.Valentine Richez, Xavier Leleu, Stéphanie Guidez et al.|Journal of Clinical Oncology|2018Cited by 2
A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: The IFM2017-03 Phase 3 TrialSalomon Manier, Thierry Façon, Jérôme Lambert et al.|SSRN Electronic Journal|2025Cited by 1